MTWM
ABUS icon

Masso Torrence Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Masso Torrence Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$2K – 79
2021
Q4 		$2K Buy
+500
New +$1.94K ﹤0.01% 348

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Masso Torrence Wealth Management's ABUS Position: Q1 2022 in Review

Masso Torrence Wealth Management sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 500 shares — an estimated $2K sold.

Masso Torrence Wealth Management first reported a position in ABUS in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • Masso Torrence Wealth Management reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • Masso Torrence Wealth Management sold 500 Arbutus Biopharma shares in Q1 2022, an estimated $2K.
  • Masso Torrence Wealth Management first reported a position in Arbutus Biopharma in Q4 2021 and held it in 1 quarter.
  • Masso Torrence Wealth Management's Arbutus Biopharma position peaked at $2K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on Masso Torrence Wealth Management's 13F filing for Q1 2022, filed 26 Apr 2022.